Antibody–drug conjugates as novel anti-cancer chemotherapeutics

Over the past couple of decades, antibody–drug conjugates (ADCs) have revolutionized the field of cancer chemotherapy. Unlike conventional treatments that damage healthy tissues upon dose escalation, ADCs utilize monoclonal antibodies (mAbs) to specifically bind tumour-associated target antigens and...

Descripción completa

Detalles Bibliográficos
Autores principales: Peters, Christina, Brown, Stuart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2015
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4613712/
https://www.ncbi.nlm.nih.gov/pubmed/26182432
http://dx.doi.org/10.1042/BSR20150089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4613712/
https://www.ncbi.nlm.nih.gov/pubmed/26182432
http://dx.doi.org/10.1042/BSR20150089

Ejemplares similares